IP Library Granted Patent US 9,796,668
Granted Patent B2
US 9,796,668 · App. 14/950,557 · Granted Oct 24, 2017

Natural product analogs including an anti-inflammatory cyanoenone pharmacore and methods of use

Inventors: Eric Anderson (Southlake, TX); Gary L. Bolton (Ann Arbor, MI); Deborah A. Ferguson (Branchburg, NJ); Xin Jiang (Coppell, TX); Robert M. Kral, Jr. (Grapevine, TX); Patrick M. O'Brien (Stockbridge, MI); Melean Visnick (Irving, TX)
Assignee: REATA PHARMACEUTICALS, INC.
C07C255/46C07D311/74C07D317/26C07D493/10C07F7/1856C07J21/003C07J41/0055C07J41/0094C07J53/001C07J71/0005C07C2601/16
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,796,668
App. No.
14/950,557
Granted
Oct 24, 2017
Kind
B2
Abstract

This invention provides novel compounds comprising the following anti-inflammatory pharmacore: wherein X, R 1 and R 2 are defined herein. Also provided are pharmaceutical compositions, kits and articles of manufacture comprising such compounds, methods and intermediates useful for making the compounds, and methods of using the compounds and compositions.

Claims (21)

1. A compound of the formula:

wherein:

R 1 and R 2 are each independently:

hydrogen; or

alkyl (C≦12) , alkenyl (C≦12) , alkynyl (C≦12) , aryl (C≦12) , aralkyl (C≦12) , heteroaryl (C≦12) , heteroaralkyl (C≦12) , acyl (C≦12) , alkoxy (C≦12) , aryloxy (C≦12) , aralkoxy (C≦12) , heteroaryloxy (C≦12) , heteroaralkoxy (C≦12) , acyloxy (C≦12) , alkylamino (C≦12) , dialkylamino (C≦12) , arylamino (C≦12) , aralkylamino (C≦12) , hetero-arylamino (C≦12) , heteroaralkylamino (C≦12) , amido (C≦12) , or a substituted version of any of these groups; or

R 1 and R 2 are taken together and are alkanediyl (C≦12) , alkenediyl (C≦12) , alkanediyl (C≦12) or alkenediyl (C≦12) ; and

R 5 and R 6 are each independently:

hydrogen, hydroxy, halo, amino, hydroxyamino, nitro, cyano, azido, or mercapto; or

alkyl (C≦12) , alkenyl (C≦12) , alkynyl (C≦12) , aryl (C≦12) , aralkyl (C≦12) , heteroaryl (C≦12) , heteroaralkyl (C≦12) , acyl (C≦12) , alkoxy (C≦12) , alkenyloxy (C≦12) , alkynyl-oxy (C≦12) , aryloxy (C≦12) , aralkoxy (C≦12) , heteroaryloxy (C≦12) , hetero-aralkoxy (C≦12) , acyloxy (C≦12) , alkylamino (C≦12) , dialkylamino (C≦12) , alkoxy-amino (C≦12) , alkenylamino (C≦12) , alkynylamino (C≦12) , arylamino (C≦12) , aralkylamino (C≦12) , heteroarylamino (C≦12) , heteroaralkylamino (C≦12) , amido (C≦12) , alkylsilyl (C≦12) , alkylsilyloxy (C≦12) , or a substituted version of any of these groups;

or pharmaceutically acceptable salts, esters, tautomers, acetals, ketals, or optical isomers thereof.

2. The compound of claim 1 , wherein R 1 and R 2 are both methyl.

3. The compound of claim 1 , further defined by the formula:

or pharmaceutically acceptable salts, tautomers, or optical isomers thereof.

4. A compound of the formula:

or pharmaceutically acceptable salts, tautomers, or optical isomers thereof.

5. A compound having the name:

(S,E)-3-(4-hydroxystyryl)-3,5,5-trimethyl-6-oxocyclohex-1-enecarbonitrile.

6. A compound selected from the group consisting of:

(S,E)-3-(4-hydroxystyryl)-3-methyl-6-oxocyclohex-1-enecarbonitrile, and

(3S)-3-(4-hydroxystyryl)-3,5-dimethyl-6-oxocyclohex-1-enecarbonitrile.

7. A pharmaceutical composition comprising as an active ingredient a compound according to claim 1 and a pharmaceutically acceptable carrier.

Assignments (9)
RELEASE OF SECURITY INTEREST Recorded Apr 9, 2025
From: BIOPHARMA CREDIT PLC
To: REATA PHARMACEUTICALS HOLDINGS, LLC; REATA PHARMACEUTICALS GLOBAL, INC.; REATA PHARMACEUTICALS, INC.
Reel/Frame 070793/0228 →
RELEASE OF SECURITY INTEREST Recorded Apr 9, 2025
From: BIOPHARMA CREDIT PLC
To: REATA PHARMACEUTICALS HOLDINGS, LLC; REATA PHARMACEUTICALS GLOBAL, INC.; REATA PHARMACEUTICALS, INC.
Reel/Frame 070793/0130 →
AMENDED AND RESTATED PATENT SECURITY AGREEMENT Recorded Jul 12, 2023
From: REATA PHARMACEUTICALS HOLDINGS, LLC; REATA PHARMACEUTICALS GLOBAL, INC.; REATA PHARMACEUTICALS, INC.
To: BIOPHARMA CREDIT PLC
Reel/Frame 064264/0557 →
PATENT SECURITY AGREEMENT Recorded May 18, 2023
From: REATA PHARMACEUTICALS HOLDINGS, LLC; REATA PHARMACEUTICALS GLOBAL, INC.; REATA PHARMACEUTICALS, INC.
To: BIOPHARMA CREDIT PLC
Reel/Frame 063697/0461 →
RELEASE OF SECURITY INTEREST Recorded Jun 24, 2020
From: OXFORD FINANCE LLC, AS COLLATERAL AGENT
To: REATA PHARMACEUTICALS, INC.
Reel/Frame 053034/0018 →
SECURITY INTEREST Recorded Jun 14, 2018
From: REATA PHARMACEUTICALS, INC.
To: OXFORD FINANCE LLC, AS COLLATERAL AGENT
Reel/Frame 046357/0605 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 2, 2015
From: ANDERSON, ERIC; FERGUSON, DEBORAH A.; JIANG, XIN; KRAL, ROBERT M., JR.; VISNICK, MELEAN
To: REATA PHARMACEUTICALS, INC.
Reel/Frame 037186/0439 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 2, 2015
From: AAPHARMASYN
To: REATA PHARMACEUTICALS, INC.
Reel/Frame 037187/0021 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 2, 2015
From: BOLTON, GARY L.; O'BRIEN, PATRICK M.
To: AAPHARMASYN
Reel/Frame 037186/0575 →
Continuity (4)
Division 13552530 · Jul 18, 2012
Continuation 12426889 · Apr 20, 2009
Provisional Application 61046363 · Apr 18, 2008
Related Publication 20160145200A1 · May 26, 2016